ACP
ITOS

Acuta Capital Partners’s iTeos Therapeutics ITOS Stock Holding History

Acuta Capital Partners’s Portfolio ITOS Stock Details ITOS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q3 		– Sell
-62,000
Closed -$1.28M – 51
2022
Q2 		$1.28M Buy
+62,000
New +$1.47M 0.71% 33

Other funds holding ITOS

RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
MAM
MPM Asset Management Boston, Massachusetts $44.5M AUM 47.28% 1-Year Est. Return
BC
Boxer Capital San Diego, California $2.04B AUM 108.39% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
BI
BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
MB
MPM BioImpact Boston, Massachusetts $1.29B AUM 141.72% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
TCM
Tang Capital Management San Diego, California $1.97B AUM 125.1% 1-Year Est. Return

Acuta Capital Partners's ITOS Position: Q3 2022 in Review

Acuta Capital Partners sold out of iTeos Therapeutics (ITOS) in Q3 2022, closing a stake of 62,000 shares — an estimated $1.28M sold.

Acuta Capital Partners first reported a position in ITOS in Q2 2022 and held it in 1 quarter. The position peaked at $1.28M in Q2 2022. 143 funds tracked by Wall St. Rank hold ITOS as of Q3 2022.

  • Acuta Capital Partners reported no remaining iTeos Therapeutics position as of Q3 2022 after selling out during the quarter.
  • Acuta Capital Partners sold 62,000 iTeos Therapeutics shares in Q3 2022, an estimated $1.28M.
  • Acuta Capital Partners first reported a position in iTeos Therapeutics in Q2 2022 and held it in 1 quarter.
  • Acuta Capital Partners's iTeos Therapeutics position peaked at $1.28M in Q2 2022.
  • 143 funds tracked by Wall St. Rank held iTeos Therapeutics as of Q3 2022.

Based on Acuta Capital Partners's 13F filing for Q3 2022, filed 14 Nov 2022.